Menu
Back to User profile » Prof. Dr. Ioana Berindan-Neagoe
Papers published by Prof. Dr. Ioana Berindan-Neagoe:
MicroRNA Dysregulation in Prostate Cancer
Schitcu VH, Raduly L, Nutu A, Zanoaga O, Ciocan C, Munteanu VC, Cojocneanu R, Petrut B, Coman I, Braicu C, Berindan-Neagoe I
Pharmacogenomics and Personalized Medicine 2022, 15:177-193
Published Date: 10 March 2022
Securidaca–saponins are natural inhibitors of AKT, MCL-1, and BCL2L1 in cervical cancer cells [Corrigendum]
Obasi TC, Braicu C, Iacob BC, Bodoki E, Jurj A, Raduly L, Oniga I, Berindan-Neagoe I, Oprean R
Cancer Management and Research 2019, 11:691-692
Published Date: 15 January 2019
Securidaca–saponins are natural inhibitors of AKT, MCL-1, and BCL2L1 in cervical cancer cells
Obasi TC, Braicu C, Iacob BC, Bodoki E, Jurj A, Raduly L, Oniga I, Berindan-Neagoe I, Oprean R
Cancer Management and Research 2018, 10:5709-5724
Published Date: 15 November 2018
RNA interference: new mechanistic and biochemical insights with application in oral cancer therapy
Buduru S, Zimta AA, Ciocan C, Braicu C, Dudea D, Irimie AI, Berindan-Neagoe I
International Journal of Nanomedicine 2018, 13:3397-3409
Published Date: 8 June 2018
The role of the pathology department in the preanalytical phase of molecular analyses
Susman S, Berindan-Neagoe I, Petrushev B, Pirlog R, Florian IS, Mihu CM, Berce C, Craciun L, Grewal R, Tomuleasa C
Cancer Management and Research 2018, 10:745-753
Published Date: 12 April 2018
The new era of nanotechnology, an alternative to change cancer treatment
Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I
Drug Design, Development and Therapy 2017, 11:2871-2890
Published Date: 27 September 2017
miRNA expression profiling in formalin-fixed paraffin-embedded endometriosis and ovarian cancer samples
Braicu OL, Budisan L, Buiga R, Jurj A, Achimas-Cadariu P, Pop LA, Braicu C, Irimie A, Berindan-Neagoe I
OncoTargets and Therapy 2017, 10:4225-4238
Published Date: 28 August 2017
Future trends and emerging issues for nanodelivery systems in oral and oropharyngeal cancer
Irimie AI, Sonea L, Jurj A, Mehterov N, Zimta AA, Budisan L, Braicu C, Berindan-Neagoe I
International Journal of Nanomedicine 2017, 12:4593-4606
Published Date: 26 June 2017
The use of rotation to fentanyl in cancer-related pain
Dima D, Tomuleasa C, Frinc I, Pasca S, Magdo L, Berindan-Neagoe I, Muresan M, Lisencu C, Irimie A, Zdrenghea M
Journal of Pain Research 2017, 10:341-348
Published Date: 9 February 2017
Double gene siRNA knockdown of mutant p53 and TNF induces apoptosis in triple-negative breast cancer cells
Pileczki V, Pop L, Braicu C, Budisan L, Bolba Morar G, del C Monroig-Bosque P, Sandulescu RV, Berindan-Neagoe I
OncoTargets and Therapy 2016, 9:6921-6933
Published Date: 11 November 2016
Normalization of gene expression measurement of tissue samples obtained by transurethral resection of bladder tumors
Pop LA, Pileczki V, Cojocneanu-Petric RM, Petrut B, Braicu C, Jurj AM, Buiga R, Achimas-Cadariu P, Berindan-Neagoe I
OncoTargets and Therapy 2016, 9:3369-3380
Published Date: 2 June 2016
Baseline blood immunological profiling differentiates between Her2– breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response
Tudoran O, Virtic O, Balacescu L, Lisencu C, Fetica B, Gherman C, Balacescu O, Berindan-Neagoe I
OncoTargets and Therapy 2015, 8:3415-3423
Published Date: 18 November 2015
Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers
Cojocneanu Petric R, Braicu C, Raduly L, Zanoaga O, Dragos N, Monroig P, Dumitrascu D, Berindan-Neagoe I
OncoTargets and Therapy 2015, 8:2053-2066
Published Date: 6 August 2015
Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
Zaharie F, Cojocneanu-Petric R, Muresan M, Frinc I, Dima D, Petrushev B, Tanase A, Berce C, Chitic M, Berindan-Neagoe I, Pileczki V, Irimie A, Tomuleasa C
International Journal of Nanomedicine 2015, 10:4897-4899
Published Date: 31 July 2015
Clinical and pathological implications of miRNA in bladder cancer
Braicu C, Cojocneanu-Petric R, Chira S, Truta A, Floares A, Petrut B, Achimas-Cadariu P, Berindan-Neagoe I
International Journal of Nanomedicine 2015, 10:791-800
Published Date: 20 January 2015
Nanopharmacology in translational hematology and oncology
Tomuleasa C, Braicu C, Irimie A, Craciun L, Berindan-Neagoe I
International Journal of Nanomedicine 2014, 9:3465-3479
Published Date: 22 July 2014
Dose intensity and autologous stem cell transplantation as salvage therapy for pediatric primary CNS malignancies
Kojima S, Cucuianu A, Takahashi Y, Berindan-Neagoe I, Florian IS, Dima D, Tomuleasa C
International Journal of Nanomedicine 2014, 9:3247-3248
Published Date: 4 July 2014
MRI-based identification of undifferentiated cells: looking at the two faces of Janus
Tomuleasa C, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A
International Journal of Nanomedicine 2014, 9:865-866
Published Date: 11 February 2014
Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
Tomuleasa C, Cucuianu A, Aldea M, Berindan-Neagoe I
International Journal of Nanomedicine 2013, 8:4043-4044
Published Date: 23 October 2013
Combining the chemotherapeutic effects of epigallocatechin 3-gallate with siRNA-mediated p53 knock-down results in synergic pro-apoptotic effects
Berindan-Neagoe I, Braicu C, Irimie A
International Journal of Nanomedicine 2012, 7:6035-6047
Published Date: 12 December 2012